Having trouble accessing articles? Reset your cache.

eGenesis pushes to bring pig organ transplants to humans with $100M series B

eGenesis is aiming to be the first to transplant genetically engineered pig organs into humans with its $100 million series B round, which will allow the Cambridge, Mass.-based company to advance multiple programs in parallel.

Fresenius Medical Care Ventures led the untranched round. New investors Leaps by Bayer

Read the full 487 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers